Project: Every Child for Younger Patients With Cancer

Description

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

Conditions

Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Project: Every Child for Younger Patients With Cancer

Condition
Adrenal Gland Pheochromocytoma
Intervention / Treatment

-

Contacts and Locations

Birmingham

Children's Hospital of Alabama, Birmingham, Alabama, United States, 35233

Mobile

USA Health Strada Patient Care Center, Mobile, Alabama, United States, 36604

Anchorage

Providence Alaska Medical Center, Anchorage, Alaska, United States, 99508

Mesa

Banner Children's at Desert, Mesa, Arizona, United States, 85202

Phoenix

Phoenix Childrens Hospital, Phoenix, Arizona, United States, 85016

Tucson

Banner University Medical Center - Tucson, Tucson, Arizona, United States, 85719

Little Rock

Arkansas Children's Hospital, Little Rock, Arkansas, United States, 72202-3591

Downey

Kaiser Permanente Downey Medical Center, Downey, California, United States, 90242

Duarte

City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010

Loma Linda

Loma Linda University Medical Center, Loma Linda, California, United States, 92354

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem
  • * Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority
  • * Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:
  • * All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant)
  • * All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
  • * The following other benign/borderline conditions:
  • * Mesoblastic nephroma
  • * Teratomas (mature and immature types)
  • * Myeloproliferative diseases including transient myeloproliferative disease
  • * Langerhans cell histiocytosis
  • * Lymphoproliferative diseases
  • * Desmoid tumors
  • * Gonadal stromal cell tumors
  • * Neuroendocrine tumors including pheochromocytoma
  • * Melanocytic tumors, except clearly benign nevi
  • * Ganglioneuromas
  • * Subjects must be =\< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \[NCTN\]) therapeutic study, for which there is a higher upper age limit
  • * All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission
  • * If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1

Ages Eligible for Study

to 25 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Oncology Group,

Douglas Hawkins, PRINCIPAL_INVESTIGATOR, Children's Oncology Group

Study Record Dates

2030-12-31